We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Antibiotics Are Prescribed for Too Long

By HospiMedica staff writers
Posted on 07 Jul 2006
Antibiotics to treat serious infections are being prescribed for too long, encouraging pathogen resistance, according to a new study.

Researchers at the Academic Medical Centre (Amsterdam, The Netherlands) compared the effectiveness of discontinuing treatment with the antibiotic amoxicillin after three days or eight days in adults admitted to a hospital with mild-to-moderate severe community-acquired pneumonia. More...
A total of 119 patients who substantially improved after the conventional three days' treatment with intravenous amoxicillin were randomly assigned to either oral amoxicillin (63 patients) or a dummy pill (56 patients) three times daily for five days. The patients were assessed after seven, 10, 14 and 28 days.

In the three day and eight day treatment groups, the clinical success rate at day 10 was 93% for both, and after four weeks it was 90% compared with 88%. Both groups had similar resolution of symptoms, x-ray results, and length of hospital stay. The results were published in the June 10, 2006, issue of the British Medical Journal.

"In general, over-use of antibiotics is increasing bacteria's resistance to them. The important thing is to assess patients after three days and if their symptoms are improving and their temperature is below 38oC then they can come off the antibiotics,” said lead author Dr. Jan Prins, an infectious diseases consultant. "A shorter duration of treatment can also help to reduce overall antibiotic consumption and resistance rates for respiratory infections.”

Pneumonia is one of the most important indications for antibiotic prescriptions in hospitals. However, a lack of evidence to support short-course therapy means it has become accepted practice to continue treatment for days after symptoms have improved.



Related Links:
Academic Medical Centre

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ureteral Dilatation Balloon
Dornier Equinox
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.